Mayne Pharma Group Ltd's stock surged 5.58% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical company.

The sharp rise appears to be driven by several positive developments. The company reported quarterly revenue of A$85.2 million, providing investors with a key financial metric. Additionally, Mayne Pharma clarified that a recent US tariff proclamation would have no material impact on its earnings, removing a potential source of uncertainty for the market.

Further supporting investor sentiment was the company's announcement that it continues to examine capital allocation strategies, which may include an on-market share buy-back program. Such a move is typically viewed positively as it can enhance shareholder value.